Abstract

AbstractPurposeTo report a case of Ocular Surface Squamous Neoplasia, in an 84 years old woman. The patient referred 4 months of red vascularized elevated corneal lesion.MethodsOur proposal was an exportation of the conjunctival corneal neoformation and histological examination. During the surgical procedure, we found an elevated lesion with feeder vessels, the surgical excision biopsy was done and the specimen was sent for histopathological evaluation, which revealed an invasive, poorly differentiated carcinoma extending to subcutis. Immunohistochemical staining for p63 gave dubious results on the integrity of the basement membrane. These findings associated with the incomplete excision of the lesion did not allow us to express a possible invasiveness in the lateral margin affected.ResultsIn the post‐operative, we used Mitomycin C 0.04% topical treatment, 4 times a day for a week, then 3 weeks off for a total of 3 cycles. During this period the patient did not display any adverse systemic or ocular reactions. At the end of the treatment, we found a complete regression of the disease. During the control at 6 months and 1 year, the patient was asymptomatic.ConclusionsDiagnosis of invasive Squamous Cell Carcinoma mainly rests on the histopathological examination of the excised lesion. No serious ocular or systemic side effects were observed during the Mitomycin C 0.04% eye drops treatment. Mitomycin C 0.04% seems to be a safe and effective treatment for ocular surface squamous neoplasia.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.